Bone · FDA Approved
PTH (1-34) Analogs
FDA-approved
01 · Overview
This class includes teriparatide, which corresponds to the 34 N-terminal amino acids of human parathyroid hormone, and abaloparatide, which the FDA label describes as a human parathyroid hormone related peptide analog rather than a PTH fragment. Both bind the PTH1 receptor on bone cells and, given intermittently, favor osteoblastic bone formation over resorption, which distinguishes them from antiresorptive therapies such as bisphosphonates.
Teriparatide is marketed as Forteo and in generic and follow-on versions, and abaloparatide as Tymlos, both listed as prescription products in FDA drug approval records.
02 · Research summary & key findings
In the pivotal teriparatide trial, 1637 postmenopausal women with prior vertebral fractures received PTH (1-34) or placebo; new vertebral fractures occurred in 14 percent of placebo patients versus 5 and 4 percent in the two hormone groups, with nonvertebral fragility fractures reduced from 6 to 3 percent and bone mineral density increased at the spine and femoral neck (PMID 11346808). The phase 3 ACTIVE trial randomized postmenopausal women to abaloparatide, placebo or open-label teriparatide for 18 months, with the percentage of participants having a new vertebral fracture as the primary endpoint (PMID 27533157). Contrary to older descriptions, neither current FDA label carries a boxed warning about osteosarcoma.
03 · Regulatory status
PTH (1-34) Analogs has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
PTH (1-34) Analogs is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
PTH (1-34) Analogs is prescribed for the conditions on its label, and it is not part of our intake. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med, 2001. PMID 11346808
- [2]Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial JAMA, 2016. PMID 27533157
Primary literature
- PubMed: "PTH Analogs"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "PTH Analogs"
Registered interventional and observational studies, including status and phase.
- PubChem: "PTH Analogs"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Bone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.